CALT News and Press, Calliditas Therapeutics AB From 02/21/23

Summary Sparsentan is approved for IgAN with a disappointing FDA label. We believe the approval is fully priced in, and we expect disappointing sales print during the first few years and fierce competition with Chinook's Atrasentan later on. Sparsentan is expected to launch in Feb 2...

Calliditas Therapeutics' ( OTCPK:CLTEF ) ( NASDAQ: CALT ) partner Everest Medicines said the Korea Ministry of Food and Drug Safety (MFDS) granted global innovative product on fast track (GIFT) designation to Nefecon to treat primary immunoglobulin A nephropathy (IgAN). ...

Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy PR Newswire STOCKHOLM , Feb. 2, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that...

Summary CALT has an approved product in the US and EU in IgAN. However, the rest of its pipeline consists of an unconvincing single product with a history of failure. They are also low on cash. Calliditas Therapeutics (CALT) is a small Swedish company that describes itself...

Summary Vera’s phase 2b ORIGIN data was underwhelming with lower than expected proteinuria reduction ~31% even at 9 months. We believe Atacicept’s commercial opportunity in IgAN is questionable due to the high degree of competition from KDNY, Otsuka, and Remegen. VERA ...

Summary 2023 should be a year of progress on kidney disease, with multiple catalysts lined up from multiple companies. Chinook Therapeutics, Inc. has the best risk-reward based on: i) valuation; ii) diversity of pipeline (ERA and anti-APRIL); and iii) clear catalyst in Q3 2023 (phase 3 ...

Swedish biopharma Calliditas Therapeutics ( NASDAQ: CALT ) announced Friday that regulators in China recommended the priority review for its marketing application seeking approval of kidney disorder therapy Nefecon. In November, Calliditas ( CALT ) announced that China's National ...

China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy PR Newswire STOCKHOLM , Dec. 30, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced th...

Calliditas Therapeutics' ( NASDAQ: CALT ) CEO Renée Aguiar-Lucander has acquired 50,000 shares through its warrant program 2019/2022. Following the new subscription, Aguiar-Lucander holds 643,000 common shares in the company. The majority of the members of management who ...

Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2019/2022 PR Newswire STOCKHOLM , Dec. 21, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced today that CEO ...